CA2261216A1 - Medical device for treatment of a gap or defect in the central nerve system - Google Patents
Medical device for treatment of a gap or defect in the central nerve system Download PDFInfo
- Publication number
- CA2261216A1 CA2261216A1 CA002261216A CA2261216A CA2261216A1 CA 2261216 A1 CA2261216 A1 CA 2261216A1 CA 002261216 A CA002261216 A CA 002261216A CA 2261216 A CA2261216 A CA 2261216A CA 2261216 A1 CA2261216 A1 CA 2261216A1
- Authority
- CA
- Canada
- Prior art keywords
- area
- nerves
- grey
- openings
- distal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
- A61B17/1128—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis of nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
Abstract
The invention relates to a medical device (1) of a biocompatible material for use in the treatment of a gap or defect in the central nerve system comprising one or more means (2, 20, 21, 22) containing connections such as holes (3) or channels (4) arranged for receiving nerve growth promoting materials or substances, which device has a proximal (5) and a distal (6) end area comprising openings (7) from the connections (3, 4) which device is marked and arranged for coupling nerves from the grey and white matter of the central nervous system at the proximal end to certain marked areas in the proximal end area and nerves in the grey and white matter at the distal end to certain marked areas in the distal end area. Preferably nerves are redirected from white to grey mass by the arrangement of the wholes and/or channels and the marking of the device. The invention also relates to a method for restoring a deficiency in the spinal cord on humans wherein the device is used and the nerves are connected with a biocompatible glue.
Description
MEDICAL DEVICE FOR TREAl~ENT OF A GAP OR ~LI nN THE CENTRAL NERVE
SYSTEM
The present invention relates to a medical device of a biocompatible m~t~ for use in the treatment of a gap or defect in the central nervous system.
Treatment that promotes functional regeneration across a complete spinal cord transection in man does not exist. In animal experiments (1), recovery after incomplete spinal cord lesions has been achieved in adults treated with myelin-associated protein antibodies while recovery after complete lesions has been 10 demonstrated in neonates (2).
Various attempts have been made over the years to find a replacement for direct nerve stump to nerve stump suturing. Much research has focused on the use of channels or tubular prostheses which permit the cut ends of the nerve to be gently 15 drawn into proximity and secured in place.
All prostheses produced so far are intended for peripheral nerves such as USP
3,833,002, USP 4,759,764, USP 4,870,966 and SE 457 598.
20 The present inventors have now found that mobility can be restored in rats having complete spinal cord gaps. The gaps have been bridged with multiple intercostal nerve grafts redirecting specific pathways from white to grey matter, and the grafted area stabilised by acidic fibroblast growth factor-cont~inin~ fibrin glue and compressive wiring of posterior spinal processes. Nerve bridges were created 25 between the peripheral nerves and the spinal cord.
It has also turned out that motility can also be resored under certain circumstances when grafting white to white and grey to grey mass if special antibodies are given to the person being treated or incorporated into inserted material cormecting the gap 30 ends of the spinal cord.
The invention relates to a medical device of a biocompatible material for use in the tre~tment of a gap or defect in the central nerve system comprising one or more means co~ g connections such as holes or ch~nnel~ arranged for receiving nerve growht promoting materials or substances, which device has a l)lo~ lal and a 5 distal end area comprising openings from the connections, characterized in that the device is marked and arranged for coupling nerves from the grey and white matterof the central nervous system at the ~roxilllal end to certain marked areas in the proximal end area and nerves in the grey and white matter at the distal end to certain marked areas in the distal end area.
The device may be marked and arranged for coupling nerves from the grey matter of the central nervous system at the plo~ al end to nerves in the grey matter at the distal end and nerves in the white matter of the central nervous system at the proximal end to nerves in the white matter at the distal end. This is especially the 15 case when antibodies are ~-lmini~trated in ordr to promote the nerves to grow together.
In a preferred device according to the invention the device or the means is marked and arranged for redirecting nerves from the grey matter of the central nervous 20 system at the proximal end to nerves in the white matter at the distal end and nerves in the white matter of the central nervous system at the proximal end to nerves in the grey matter at the distal end.
The device can be used in the tre~hnent of complete or partial gaps or defect in the 25 central nervous system. It may consist of one or more means comprising holes or channels arranged for receiving nerve growth promoting materials or substances, which device has a prox .mal and a distal end area comprising openings from the holes or channels. The openings and/or the end areas may be marked for easily coupling nerves in the grey matter of the central nervous system at the proximal end 30 of the gap to nerves in the white matter of the central nervous system at the distal end and nerves from the white matter in the distal end to nerves in the grey matter of the proximal end.
The expressions proximal and distal refer to direction to and from the head respectively of the individual receiving the transplant.
Preferably the device redirects descending motor pathways from proximal white todistal grey matter, and ascending pathways from distal white to proximal grey matter.
The device may consist of one means that has a substantially cylindrical form complising channels bridging openings in a first part of the area of the proximal end and openings in a second part of the area of the distal end and ch~nnels bridging openings in the second part of the area of the proximal end and openings in the first 15 part of the area of the distal.
The end area can have any suitable form and be planar or non planar such as curved or spherical.
20 In another embodiment of the invention the device may comprise one or more means having a subst~nt~ y flat or plate like form. Tubes of biocompatible or biodegradable m~t~ri~l Co~ g growth promoting material and/or Schwans cells and/or one or more peripheral nerves are threaded through the holes of the plate or plates. When using a nerve fibre or bundles of nerve fibres the tubes may not be25 needed.
It is ~)lerelled to use as many fine nerves as possible. In the experiment with rats described below 18 peripheral nerves were used to bridge one gap of the spinal cord. It has turned out that it is possible to use even more nerves. Therefore it is 30 postulated that upp to 200 nerves may be used on humans, such as 25-150, preferably 50-100 nerves.
It is also possible to use a device having one or more means with substantially cylindrical form and one or more means having a subst~n1~lly flat or plate like form. One means with cylindrical form can be ~ uu~lded by one or more means 5 with plate like form.
The means may also be one or more tubes of a biocompatible material to be filledwith the growth promoting substance and put in place in the spinal cord. The invention also relates to the use of such tubes. The device and means may also have 10 other forms and can e.g. be moulded to suit the subject to be treated When plates only are used they may be threaded with bundles of nerves or with tubes of the biocompatible material filled with the growth-promoting substance.
Thus the device may also comprise one or more plates and tubing to be filled when 15 used.
In order to facilitate the redirection of the grey and white matter, the areas of the proximal and distal ends respectively of the means are divided in a first and a second part. The first and the second areas may have any form. It is possible to20 simply divide the end area in two parts, that may be of the same or of different size Preferably the first area is a central area and the second area is a peripheral area sit~l~ted subst~nti~lly around the central area. It is however also pûssible that the areas have one or more parts thereof i~ ling or sticking into each other with or without connection(s) to the main part area.
Preferably the device consist of one cylindrical means having a first peripheral part and a second central part of the proximal and distal end area connected to the white and grey region respectively of both ends of the gap. Channels going from the peripheral part of one end are being redirected to end up in the central part of the 30 other end of the cylinder and vise versa.
In order to enhance long distance regeneration it is l -efel~ble to let one or more ch~nnçl~ or bundles of nerve fibres pass the gap and insert the end of the nerves or channels further down the spinal cord. Therefore the device or the means may have some of the ch~lmel~ ending at the side area and not at the distal end area. ForS example a nerve is introduced in the white matter of the pro~ al end of the gap and led through a channel that opens up in the side area of the device. It is then introduced through the white matter further down beyond the gap into the grey matter.
10 The means of the device may be marked. The first part of the proximal end area may be marked in the same way as the first part of the distal end area as is shown in Fig. la and lb.
When the device comprises one cylindrical means the first (peripheral) part of both 15 end areas can be marked in a different way from the second (central) part, e.g. white and grey to correspond to the colours of the spinal cord. Marking may not be needed when the device has a transverse end area and first and second parts of the samesize as the white and grey zones of the transverse area of the spinal cord.
20 In another embodiment the first part of the proximal end area of a means is marked in the same way as the second part of the distal end area and the second part of the proximal end area is marked in the same way as the first part of the distal end area as is means 21 in Fig. 2. This nl~rking may be practical when only one plate is used.
It is, however, also possible to use one or more plates without marking them.
The grey matter lies in the centre of the spinal cord in the form of a thick H or a butterfly surrounded by the white matter. There will be less crossing over of bundles of nerves or of channels if the first and second areas are more or less in conformity with the pattern of white and grey matter respectively in the CNS. Moreover there 30 will be still less crossing over if the switches between the different areas take place -WO 98/Wlg7 PCTISE97/01311 in the same halves or region of the cross section of the means. Thus, the switches are especially made in the same left (Fig 4E) or right side region of the spinal cord.
The device may be marked e.g. by a vertically directed line (e.g. when the device 5 has a plate like form) or an area (e.g. when the device has a cylindrical form) in order to make the switches from white to grey matter in subst~nt~ y the same left or right part of the spinal cord as was done in the rat experiment (fig 4E).
When two means in the form of plates are used they may be arranged as follows. A10 first plate is intended to be placed near the proximal end of the gap and a second plate is to be placed near the distal end of the gap. The proximal and distal end area of the first and second plate has differently marked first and second parts e.g. a white first area and a grey second part in both plates (see Fig. 3). The openings in the first part of the distal end area of the first plate and the openings of the second 15 part of the proximal end area of the second plate are marked with figures e.g. 1 to n.
The openings in the second part of the distal end area of the first plate and the openings of the first part of the proximal end area of the second plate are marked with different figures e.g. n+l to n+m.
20 The m~rking may be in the form of dirrelelll biocompatible colouring substances or ~lirrere~lt p~ rn~.
According to the invention it is also possible to combine redirecting white to grey mass with direct coupling white to white and grey to grey mass using special 25 antibodies. Such a device may contain isolated areas in the first part marked in the same way as the second part and vice versa, in order not to redirect only some nerves that are coupled to the isolated areas using the antibodies.
The growth promoting material may be any ph~rm~ceutical acceptable m~t~ri~l or 30 substance m~king the grey or white matter preferably the white matter growing. It may be a nerve growth enhancer such as for example a growth factor or active analogue, fragment or derivative thereof. One or more fibres, such as a bundle of numerous fibres or axons of a peripheral nerve and / or Schwans cells may be used.
The nerves may be both monofascicular and polyfascicular. Also mixtures of the above mentioned materials and substances can be used possibly together with a 5 glue, that does not negatively affect the growth of nerves. The material may come from the individual to be treated or from other individuals from the same or some other species.
Preferably nerves coming from the ribs such as intercostal nerves are taken out from 10 the individual to be treated and cut into pieces. These nerve pieces or parts thereof are inserted in the holes or charmels in the device. It is preferred to have as many nerves as possible as more and better functions are likely to be restored the more bridges that are created. One can use 1 to 100, preferably 9 to 75 especially 15 to 40 bundles of nerve fibres.
The holes and the channels may have any transverse cross sectional form such as round, oval or square. They are preferably general tubular with round or oval lumen.
The diameter may be from 1 ,um to 5 mm. Preferably visible bundles of peripheralnerve fibres are inserted in the channels that have a diameter of about 0.2 mm - 3 20 mm, especially 0.5 rnm - 2 mm.
The device can be delivered without any growth promoting material and be used together with e.g. peripheral nerves or Schwans cells from the individual to be transplanted. It is however also possible to deliver the device with a growth 25 promoting material put in place possibly together with pharmaceuticals or sùbstances preventing microbial and immunological influence on the m~teri~l du~ng transport and storage or in the patient body. The device may also contain growthfactors such as bioactive neotrophic factors e.g. aFGF incorporated into the material of the device or in the holes and/or channels. The growth factor may be present in a 30 gradient concentration that may increase in the ploxill~al or distal direction.
Different gradients can be used for the space holding nerves coming from the white and grey matter respectively.
The device and the means may have any form. The transverse sectional area may for 5 example be round, oval, square or rect~n~ r. Preferably it has about ~e same form and area as the transverse section of the gap in the spinal cord of the individual receiving the implant. The size of the individual affects the size of the spinal cord.
Further the spinal cord is thicker in the regions where the nerves to the arms and legs come out. It is also possible to treat a complete or partial gap. Taking this into 10 account, and with regard to the fact that the means may be plate like or have the form of a cylinder, the device may be produced in different sizes. The length in the direction of the spinal cord may be about 0.2 cm to 5 cm, preferably 0.5 cm to 4 cm.
The length of the device is depending on the length of each means that it is composed of. The transversal area of the device and means may vary f~om about 0.3 15 cm2 to about 4 cm2.
The invention also relates to a method for restoring a deficiency in the spinal cord on hllm~n~ comprising filling a device of a biocompatible material with nerves and/or Schwans cells, possibly aslo growth promoting material and possibly also a 20 biocompatible glue and connecting white to grey mass of the spinal cord. Whenspecial antibodies are used it is also possible to couple the nerves from white to white mass and from grey to grey mass It is also possible to combine the two dirrerelll ways of coupling the mass of the 25 central nerve system and couple some of the nerves to the same sort of mass (i.e.
white to white and grey to grey) and some other nerves from white to grey.
The device may be composed of any biocompatible material such as, for example, polyethylene vinyl-acetate (EVA); or of biocompatible hydrogels, such as polyvinyl 30 pyrolidone, polyethylene oxide (PEO), polyurethanes, acrylates, or mixtures thereof. Preferable acrylates include methacrylates or hydroethylmethacrylates.
Alternatively it may be composed of a bioresorbable, or bioabsorbable biocompatible polymer, such as a polyanhydride, polyester, or mixtures thereof;
Poly-alpha-hydroxy acids (PGA), polylactic acid, copolymers of lactic and glycolic acids, and said polymers copolymerized with other polyesters such as epsilon -S caprolactone; copolymers having a glycolic acid ester and trimethylene carbonatelinkages, e.g. the copolymer in the MAXON (American Cyanamid Co~ y, Wayne NJ. 07470, USA) suture; polydioxanone; polyesters formed from diols and succinic and/or oxalic acid, isomorphic copolyoxalates and poly(alkylene) oxalates;
polymers made from unsyrnmetrically-substituted 1.4 - dioxane-2.5-diones.
One can also use silicon, connective tissue fibres such as collagen, polyglycolic acid, composite made of collagen and glycosaminoglucan (see USP 4,280,954).
The m~t~ l of the device is ~l~felably permeable to body liquids and substances in 15 order to facilitate for e.g. blood vessels to grow into the device. The material shall have qualities in order to hold and keep the nerve fibres in place. Connective tissue fibres such as collagen are suitable.
The device may be produced by using flexible tubes around which the 20 biocompatible material is moulded. The flexible tubes are bent to change ~e direction of the charmels from the first area of the proximal end to the second area of the distal end and vice versa to create channels ch~nging direction from white to grey matter. The tubes are then drawn out from the device.
25 Devices, such as plates intended for ch~ngin~ the direction from white to grey outside the means or between the means, can be produced as described in WO
90/05552.
The device is ple~erably delivered with a thread inserted in the channels. When 30 used, bundles of nerves are tied to the thread and drawn through the channels.
W O 9~04197 PCT/SEg7/01311 When used the device compri~ing nerve bundles or channels of biocompatible material co~ pi Schwans cells and/or other nerve growth promoting material are treated with a biocompatible glue co~"~ one or more growth factors.
5 The glue to be used according to the invention is preferably a fibrin glue co..~ g 50-200 mg /ml, preferably 100 mg/ml of fibrinogen and 0.2 ~lg - 20 ~lg per ml especially lllg - 5,ug per ml, especially 2.1 ,ug/ml of aFGF (acidic fibroblast growth factor).
10 The fibrin glue may be a fibrinogen based compound with double sealant components (Beringplast R P, Behring, Behringwerke AG, M~-gbulg, Germany), cont~inin~ a vial A with fibrinogen concentrate consisting of 115-232 mg dry substance, cont~ining a human plasma protein fraction with 65-115 mg fibrinogen and a human plasma l)rotei~l fraction with a factor XIII activity of 40-80 U, and a 15 vial B with aplot~ solution consisting of 1 ml solution cont~ining 1000 KI~J
bovine lung aproli~ and a vial C of thrombin consisting of 4.9- 11.1 mg dry substance cont~ining a human plasma pro~eill fraction with a thrombin activity of 400-600 IU and a vial D with a calcium chloride solution consisting of 2.5 ml solution cont~ining 14.7 mg calcium chloride 2H2O (40 mmol).
The advice of the supplier is followed and the aFGF is added to the vial A when used.
The invention will now be described with reference to the figures of which:
Fig la is a perspective view of one embodiment of the invention and the ends of the central nervous system at a gap, where the pathways in the central nerve systen is redirected, 30 Fig lb is a perspective view of another embodiment of the invention where the pathways are recoupled from white to white and from grey to grey mass, W 0 98/04197 ~l/~h~7/ol3 Fig 2 is a view from above of a device according to the invention clmci~ting of two plates, - 5 Fig 3 is a view from above as in Fig 2 showing possible m~rkin~ of the plates with figures in order to facilitate the threading of nerves through the plates.
Fig 4 A-F show the results from grafting of rat spinal cord, 4 A-C show microphotographs illustrating st~inings of sections through spinal cord se~ nt~, 4D
10 hindlimb function, 4E schematic illustration of white-to-grey matter nerve bridges and 4F summary of data from ~nim~l~ and Fig 5 A-F show morphology and sequential videoframes from experimental ~nim~
15 In the device la of Fig 1 the means 2 has the form of a cylinder with a proximal end area 5 and a distal end area 6 having first 8 and second 9 parts. The first parts 8 and the second parts 9 of the proximal and distal ends 5 and 6 are white and shaded respectively. The device contains channels 4 of which three are shown in the drawing. One channel 4 leads from the first part 8 of the proximal end area 5 to the 20 second part 9 of the distal area 6. Another channel leads from the second part 9 of the proximal end area 5 to the first part 8 of the distal end area 6. One of thechannels 4 ends in an opening 7 on the side area 14 of the device in order to beshunted passed the distal end of the CNS gap and introduced into the CNS furtherdown at a suitable angle through the white into the grey matter. The channels have 25 been threaded with bundles of nerves (not shown).
The end areas having parts marked in dirrelcl~ ways m~king it easy to see e.g. that channels coming out from the white first parts 8 of the ploxi",al end area 5 are to be inserted into the white matter 11 of the end area of the plox~l,al gap 10. Ch~nnel~
30 coming from the grey second area 9 in the distal end 6 of the device are inserted in the grey matter 13 of the end area of the distal gap 12. Correspondingly other , channels coming out from the white first 8 and grey second 9 part of the end areas 5 and 6 of the device are inserted into the mass of the end areas of the CNS gap having the same colour. With the device of figure 1 descending motor pathways from proximal white were coupled to distal grey matter and ascending pathways 5 from distal white to ~lox~ al grey matter according to the arrows.
The device of Fig. lb is intended to be used together with a material such as certain antibodies, that can induce growth in the nerve material. Therefore the pathwaysneed not to be redirected. The device comprises one means 20 in which two 10 channels 4 are shown to lead from the first part 8 of the proximal end area 5 to the first part 8 of the distal end area 6. Another channel 4 is shown to lead from the second part 9 of the proximal end area 5 to the second part 9 of the distal end areda 6. Thus, no redirection is made. The device of figure lb may also have channels ending in openings on the side area 14 to be shunted passed the gap and introduced 15 into the CNS further down (not shown).
Fig 2 shows the proximal and distal end areas of a device 1 consisting of two means 21 and 22 in the form of two plates with wholes 3 through which bundles of nerves or tubes filled with growth promoting material such as Schwans cells may be 20 threaded according to the dashed lines. The ~loxLl,.al and distal ends of the two plates are shown. The plates 21, 22 are marked lP and 2P respectively in order to be placed in the right order and with the pro~L~n~al ends towards the head of the patient.
The proximal end 5 of the first plate 21 marked " lP" has a white first part 8' and a grey second part 9' to show where to insert the tubes or nerve bundles into the white 25 and grey matter of the proximal CNS gap later on. The distal end 6 of the first plate is marl~ed in order to direct the threading of the nerves coming out of the first plate, the first part 8' being grey and the second part 9' being white. The proximal part 5 of the second plate 22 is marked to receive the nerves from the right part of the first plate in order to cha~ge the direction from white to grey. Thus, the first part 8 of the 30 proximal end 5 is white and the second part 9 is grey, the first 8 and second part 9 respectively of the distal end 6 of the second plate 22 being marked in the same WO 98/04197 PCr/SE97/01311 way, white and grey. The plates may change places but in such a case the crossing over from white to grey area will not take place between the plates but after the second plate. When used, glue is placed between the plates and at the site of insert or in the spinal cord.
It is also possible to mark the first and second part of the proximal area of the first plate white and grey as in figure 2 but instead of marking the areas of the distal end of the first plate and the proximal area of the second plate openings 7 of the holes 3 in these areas may be numbered in order to direct the threading as shown in 10 figure 3 .
When m~king and numbering the wholes it is possible to avoid or minimise crossing of the tubes or nerve bundles and to keep the redirection between white and greymatter in the same left or right part of the device and the spinal cord.
Tests showin~ Spinal Cord Repair in Adult Paraple~ic Rats and Partial Restoration of Hindlimb Function (Science, July 26, 1996, in press) Complete spinal cord gaps in adult rats were bridged with multiple intercostal nerve 20 grafts redirecting specific pathways from white to grey matter, and the grafted area stabilised by acidic fibroblast growth factor-cont~inin~; fibrin glue and compressive wiring of posterior spinal processes. Hindlimb function improved progressively during the first 6 months as assessed by two generally accepted scoring systems.The corticospinal tract regenerated through the grafted area to the lumbar 25 enlargement, as did several bulbospinal pathways. Together these data suggest a possible repair strategy for spinal cord injury.
To avoid ambiguities, and to model the most severe clinical scenario, we studiedadult rats with complete surgical transection of the spinal cord including removal of 30 5 mm of the cord at T8. Histology of excised pieces of spinal cord demonstrated complete transection (Fig. 4A). We then proceeded with a repair strategy (3).
We used peripheral nerve implants (4) to bridge the gap in the spinal cord (Fig. 4B
and C and Fig. 5B) and found that mllltiple fine nerve implants (18 nerves to bridge one gap) gave better precision than the use of fewer thicker nerves. To evade 5 oligodendroglial ~roleills that inhibit axon regeneration (5), we re-routed regenerating pathways from non-permissive white to permissive grey matter (6).
The peripheral nerve bridges thus redirected descending motor pathways from proximal white to distal grey matter, and ascending pathways from distal white to proximal grey matter (Fig. 4E), taking into account the specific anatomy of rat 10 descending and ascending pathways (7). To stabilise the lesioned area and theperipheral nerve bridges, the grafted area was filled with a fibrin-based tissue glue that does not impair nerve fibre growth (8), and fixed the v~leblal column in dorsiflexion by wiring (9).
15 Acidic FGF is a norrnal spinal cord constituent ( 10). Lacking a signal sequence, it is thought to be sequestered within cells, and released only after d~m~e.
Consequently, FGF may be involved in repair (11). It also decreases gliosis and enhances nerve fibre development in spinal cord grafts (12). Mixing aFGF into fibrin glue allows slow release (13).
~nim~ were followed over time for signs of functional recovery and rated by two independent blinded observers using the CBS (14) and the OFWS (15). Key responses were video-recorded. l~intllimb function in ~nim~l~ subjected to the five-step procedure improved significantly, be~innin~ three weeks after operation and25 continl-in~ through the year of observation (Fig. 4D). Anim~l~ subjected to nil~tçral treatment also improved, although to a lesser degree. Four different control groups (14 transection only, 5 cord removal only, 3 white-to-white matter bridging, 2 omissions of aFGF), did not improve (Fig. 4D). Improvement was manifest as appearance of a functional posture in hindlimbs (usually flexion at hips, 30 then knees, then dorsiflexion at ankles). In controls, hindlimbs remained ext~n~le(l and ext~rn~lly rotated. Improvement was symmetrical in 6 cases (28%), and asymmetrical in the rest. Locomotion involved trotting rather than ambling gait (Fig.
5 H-J). Hin-llimbs partially supported body weight and movements were noted in the three major joints. Such movements were not seen in any of the control groups.
We also found strongly statistically positive effects on contact placing scores of 5 both groups with full treatment (Fig. 4D), suggesting that functional recovery involves the corticospinal tract (2).
Anterograde wheat-germ agglutinin horseradish peroxidase (WGA-HRP) tracing from the sensorimotor cortices and retrograde WGA-HRP tracing from the lumbar 10 enlargements were used to document fibre tract regeneration (Fig. lF, 16). The spinal cord and brain were analysed and labelled nerve cell bodies counted (17).Sections from the engrafted area were analysed with cresyl violet or antibodies against neurofilament and glial fibrillary acidic protein (GFAP) to illustrate morphology, nerve fibres in the bridges, and the degree of gliosis. Anterograde 15 tracing is exemplified by one treated animal (Fig. 4F, SE, SF, SG) with labelled fibres descending in the dorsal funiculus of the proximal stump, traversing the bridging grafts, and reaching grey matter of the proximal portion of the distal stump.
Fibres descended at the interface between the dorsal funiculus and dorsal grey matter and ended along the dorsomedial aspect of the dorsal horn in regions 20 adjacent to substantial gelatinosa in the lumbar enlargement. The labelled fibres were thus found in areas corresponding to the pathway of the rat corticospinal tract as shown in rodent cortical ablation studies (7). In the four other anim~l~ analysed by anterograde tracing (Fig. 4F), labelled fibres traversed the bridging grafts and were found in grey matter to T11, Tl 1-12, T12 or L1-2. In four transected control 25 ~nim~l~ and in one animal subjected to white-to-white matter bridging plus aFGF, the corticospinal tracts did not reach the distal spinal cord stu~nps. Anterograde tracing of controls indicated no connections to the distal stumps (Fig. 4F).
Application of WGA-HRP to the lesioned lumbar spinal cord led to labelling of 30 motoneurons in layers III-V of hindlimb motor areas bilaterally in cortex cerebri in two of the three treated ~nim~l~ (Fig. SA). Labelled neurones were also observed in .. . . .
WO 98/041g7 PCT/SE97/01311 dorsal tegmentum, the lower limb areas of the red nuclei, reticular nuclei, and raphe nuclei in all treated ~nim~l~ A few raphe neurones (8 cells) were labelled in one of the three transected controls and one grafted animal without aFGF (56 cells).
Numerous raphe neurones were labelled in ~nim~l~ receiving the five-step 5 procedure. Thus a substantial number of regenerating descending axons, incl~ ing the corticospinal tract and other supraspinal neurones, appears essential for functional recovery. Anim~l~ with improvement of hind limb function showed evidence of regeneration of both the motor initiation and the voluntary gait modification cir-iuil~ to the spinal cord central pattern ge~ierator (18), suggesting 10 that these reconnections allowed ~nim~l~ to partially control their hin(llimhs. The degree of functional recovery appeared correlated to the degree of regeneration of motor fibre systems (Fig. 4F). GFAP-immunohistochemistry demonstrated large cysts and wide GFAP-poor gaps between the cord stumps (4.7~0.86 mm, n = 5) in C1 controls, whereas ~nim~l~ receiving the full repair strategy had significantly 15 shorter GFAP-poor gaps (0.7~t0. 19 mm, n = 4; pc 0.001, ANOVA). The bridge grafts in the latter group displayed rich neurofilament immunoreactivity.
Researchers have studied many different models of spinal cord injury in ~nim~lc.Incomplete spinal cord lesions such as hemisections, contusions, compressions, and dirre~ t chemical or mechanical partial lesions have generated valuable information 20 about reactive and compensatory changes, but several of these models are lesssuitable for studies of functional recovery caused by regeneration of cut axons We have shown that our procedure can lead to a substantial degree of structural andfunctional recovery in the completely transected adult rat spinal cord, including regeneration of pyramidal tract axons, hindlimb movements and weight support. It25 remains to be seen to which extent our technique is applicable to the chronic paraplegic state and to hllm~n~.
References:
30 1. E. Puchala, W. Windle, Exp. Neurol. 55, 1-42 (1977); L. Olson et al., Brain Res. Bull. 9, 519-537 (1982).
SYSTEM
The present invention relates to a medical device of a biocompatible m~t~ for use in the treatment of a gap or defect in the central nervous system.
Treatment that promotes functional regeneration across a complete spinal cord transection in man does not exist. In animal experiments (1), recovery after incomplete spinal cord lesions has been achieved in adults treated with myelin-associated protein antibodies while recovery after complete lesions has been 10 demonstrated in neonates (2).
Various attempts have been made over the years to find a replacement for direct nerve stump to nerve stump suturing. Much research has focused on the use of channels or tubular prostheses which permit the cut ends of the nerve to be gently 15 drawn into proximity and secured in place.
All prostheses produced so far are intended for peripheral nerves such as USP
3,833,002, USP 4,759,764, USP 4,870,966 and SE 457 598.
20 The present inventors have now found that mobility can be restored in rats having complete spinal cord gaps. The gaps have been bridged with multiple intercostal nerve grafts redirecting specific pathways from white to grey matter, and the grafted area stabilised by acidic fibroblast growth factor-cont~inin~ fibrin glue and compressive wiring of posterior spinal processes. Nerve bridges were created 25 between the peripheral nerves and the spinal cord.
It has also turned out that motility can also be resored under certain circumstances when grafting white to white and grey to grey mass if special antibodies are given to the person being treated or incorporated into inserted material cormecting the gap 30 ends of the spinal cord.
The invention relates to a medical device of a biocompatible material for use in the tre~tment of a gap or defect in the central nerve system comprising one or more means co~ g connections such as holes or ch~nnel~ arranged for receiving nerve growht promoting materials or substances, which device has a l)lo~ lal and a 5 distal end area comprising openings from the connections, characterized in that the device is marked and arranged for coupling nerves from the grey and white matterof the central nervous system at the ~roxilllal end to certain marked areas in the proximal end area and nerves in the grey and white matter at the distal end to certain marked areas in the distal end area.
The device may be marked and arranged for coupling nerves from the grey matter of the central nervous system at the plo~ al end to nerves in the grey matter at the distal end and nerves in the white matter of the central nervous system at the proximal end to nerves in the white matter at the distal end. This is especially the 15 case when antibodies are ~-lmini~trated in ordr to promote the nerves to grow together.
In a preferred device according to the invention the device or the means is marked and arranged for redirecting nerves from the grey matter of the central nervous 20 system at the proximal end to nerves in the white matter at the distal end and nerves in the white matter of the central nervous system at the proximal end to nerves in the grey matter at the distal end.
The device can be used in the tre~hnent of complete or partial gaps or defect in the 25 central nervous system. It may consist of one or more means comprising holes or channels arranged for receiving nerve growth promoting materials or substances, which device has a prox .mal and a distal end area comprising openings from the holes or channels. The openings and/or the end areas may be marked for easily coupling nerves in the grey matter of the central nervous system at the proximal end 30 of the gap to nerves in the white matter of the central nervous system at the distal end and nerves from the white matter in the distal end to nerves in the grey matter of the proximal end.
The expressions proximal and distal refer to direction to and from the head respectively of the individual receiving the transplant.
Preferably the device redirects descending motor pathways from proximal white todistal grey matter, and ascending pathways from distal white to proximal grey matter.
The device may consist of one means that has a substantially cylindrical form complising channels bridging openings in a first part of the area of the proximal end and openings in a second part of the area of the distal end and ch~nnels bridging openings in the second part of the area of the proximal end and openings in the first 15 part of the area of the distal.
The end area can have any suitable form and be planar or non planar such as curved or spherical.
20 In another embodiment of the invention the device may comprise one or more means having a subst~nt~ y flat or plate like form. Tubes of biocompatible or biodegradable m~t~ri~l Co~ g growth promoting material and/or Schwans cells and/or one or more peripheral nerves are threaded through the holes of the plate or plates. When using a nerve fibre or bundles of nerve fibres the tubes may not be25 needed.
It is ~)lerelled to use as many fine nerves as possible. In the experiment with rats described below 18 peripheral nerves were used to bridge one gap of the spinal cord. It has turned out that it is possible to use even more nerves. Therefore it is 30 postulated that upp to 200 nerves may be used on humans, such as 25-150, preferably 50-100 nerves.
It is also possible to use a device having one or more means with substantially cylindrical form and one or more means having a subst~n1~lly flat or plate like form. One means with cylindrical form can be ~ uu~lded by one or more means 5 with plate like form.
The means may also be one or more tubes of a biocompatible material to be filledwith the growth promoting substance and put in place in the spinal cord. The invention also relates to the use of such tubes. The device and means may also have 10 other forms and can e.g. be moulded to suit the subject to be treated When plates only are used they may be threaded with bundles of nerves or with tubes of the biocompatible material filled with the growth-promoting substance.
Thus the device may also comprise one or more plates and tubing to be filled when 15 used.
In order to facilitate the redirection of the grey and white matter, the areas of the proximal and distal ends respectively of the means are divided in a first and a second part. The first and the second areas may have any form. It is possible to20 simply divide the end area in two parts, that may be of the same or of different size Preferably the first area is a central area and the second area is a peripheral area sit~l~ted subst~nti~lly around the central area. It is however also pûssible that the areas have one or more parts thereof i~ ling or sticking into each other with or without connection(s) to the main part area.
Preferably the device consist of one cylindrical means having a first peripheral part and a second central part of the proximal and distal end area connected to the white and grey region respectively of both ends of the gap. Channels going from the peripheral part of one end are being redirected to end up in the central part of the 30 other end of the cylinder and vise versa.
In order to enhance long distance regeneration it is l -efel~ble to let one or more ch~nnçl~ or bundles of nerve fibres pass the gap and insert the end of the nerves or channels further down the spinal cord. Therefore the device or the means may have some of the ch~lmel~ ending at the side area and not at the distal end area. ForS example a nerve is introduced in the white matter of the pro~ al end of the gap and led through a channel that opens up in the side area of the device. It is then introduced through the white matter further down beyond the gap into the grey matter.
10 The means of the device may be marked. The first part of the proximal end area may be marked in the same way as the first part of the distal end area as is shown in Fig. la and lb.
When the device comprises one cylindrical means the first (peripheral) part of both 15 end areas can be marked in a different way from the second (central) part, e.g. white and grey to correspond to the colours of the spinal cord. Marking may not be needed when the device has a transverse end area and first and second parts of the samesize as the white and grey zones of the transverse area of the spinal cord.
20 In another embodiment the first part of the proximal end area of a means is marked in the same way as the second part of the distal end area and the second part of the proximal end area is marked in the same way as the first part of the distal end area as is means 21 in Fig. 2. This nl~rking may be practical when only one plate is used.
It is, however, also possible to use one or more plates without marking them.
The grey matter lies in the centre of the spinal cord in the form of a thick H or a butterfly surrounded by the white matter. There will be less crossing over of bundles of nerves or of channels if the first and second areas are more or less in conformity with the pattern of white and grey matter respectively in the CNS. Moreover there 30 will be still less crossing over if the switches between the different areas take place -WO 98/Wlg7 PCTISE97/01311 in the same halves or region of the cross section of the means. Thus, the switches are especially made in the same left (Fig 4E) or right side region of the spinal cord.
The device may be marked e.g. by a vertically directed line (e.g. when the device 5 has a plate like form) or an area (e.g. when the device has a cylindrical form) in order to make the switches from white to grey matter in subst~nt~ y the same left or right part of the spinal cord as was done in the rat experiment (fig 4E).
When two means in the form of plates are used they may be arranged as follows. A10 first plate is intended to be placed near the proximal end of the gap and a second plate is to be placed near the distal end of the gap. The proximal and distal end area of the first and second plate has differently marked first and second parts e.g. a white first area and a grey second part in both plates (see Fig. 3). The openings in the first part of the distal end area of the first plate and the openings of the second 15 part of the proximal end area of the second plate are marked with figures e.g. 1 to n.
The openings in the second part of the distal end area of the first plate and the openings of the first part of the proximal end area of the second plate are marked with different figures e.g. n+l to n+m.
20 The m~rking may be in the form of dirrelelll biocompatible colouring substances or ~lirrere~lt p~ rn~.
According to the invention it is also possible to combine redirecting white to grey mass with direct coupling white to white and grey to grey mass using special 25 antibodies. Such a device may contain isolated areas in the first part marked in the same way as the second part and vice versa, in order not to redirect only some nerves that are coupled to the isolated areas using the antibodies.
The growth promoting material may be any ph~rm~ceutical acceptable m~t~ri~l or 30 substance m~king the grey or white matter preferably the white matter growing. It may be a nerve growth enhancer such as for example a growth factor or active analogue, fragment or derivative thereof. One or more fibres, such as a bundle of numerous fibres or axons of a peripheral nerve and / or Schwans cells may be used.
The nerves may be both monofascicular and polyfascicular. Also mixtures of the above mentioned materials and substances can be used possibly together with a 5 glue, that does not negatively affect the growth of nerves. The material may come from the individual to be treated or from other individuals from the same or some other species.
Preferably nerves coming from the ribs such as intercostal nerves are taken out from 10 the individual to be treated and cut into pieces. These nerve pieces or parts thereof are inserted in the holes or charmels in the device. It is preferred to have as many nerves as possible as more and better functions are likely to be restored the more bridges that are created. One can use 1 to 100, preferably 9 to 75 especially 15 to 40 bundles of nerve fibres.
The holes and the channels may have any transverse cross sectional form such as round, oval or square. They are preferably general tubular with round or oval lumen.
The diameter may be from 1 ,um to 5 mm. Preferably visible bundles of peripheralnerve fibres are inserted in the channels that have a diameter of about 0.2 mm - 3 20 mm, especially 0.5 rnm - 2 mm.
The device can be delivered without any growth promoting material and be used together with e.g. peripheral nerves or Schwans cells from the individual to be transplanted. It is however also possible to deliver the device with a growth 25 promoting material put in place possibly together with pharmaceuticals or sùbstances preventing microbial and immunological influence on the m~teri~l du~ng transport and storage or in the patient body. The device may also contain growthfactors such as bioactive neotrophic factors e.g. aFGF incorporated into the material of the device or in the holes and/or channels. The growth factor may be present in a 30 gradient concentration that may increase in the ploxill~al or distal direction.
Different gradients can be used for the space holding nerves coming from the white and grey matter respectively.
The device and the means may have any form. The transverse sectional area may for 5 example be round, oval, square or rect~n~ r. Preferably it has about ~e same form and area as the transverse section of the gap in the spinal cord of the individual receiving the implant. The size of the individual affects the size of the spinal cord.
Further the spinal cord is thicker in the regions where the nerves to the arms and legs come out. It is also possible to treat a complete or partial gap. Taking this into 10 account, and with regard to the fact that the means may be plate like or have the form of a cylinder, the device may be produced in different sizes. The length in the direction of the spinal cord may be about 0.2 cm to 5 cm, preferably 0.5 cm to 4 cm.
The length of the device is depending on the length of each means that it is composed of. The transversal area of the device and means may vary f~om about 0.3 15 cm2 to about 4 cm2.
The invention also relates to a method for restoring a deficiency in the spinal cord on hllm~n~ comprising filling a device of a biocompatible material with nerves and/or Schwans cells, possibly aslo growth promoting material and possibly also a 20 biocompatible glue and connecting white to grey mass of the spinal cord. Whenspecial antibodies are used it is also possible to couple the nerves from white to white mass and from grey to grey mass It is also possible to combine the two dirrerelll ways of coupling the mass of the 25 central nerve system and couple some of the nerves to the same sort of mass (i.e.
white to white and grey to grey) and some other nerves from white to grey.
The device may be composed of any biocompatible material such as, for example, polyethylene vinyl-acetate (EVA); or of biocompatible hydrogels, such as polyvinyl 30 pyrolidone, polyethylene oxide (PEO), polyurethanes, acrylates, or mixtures thereof. Preferable acrylates include methacrylates or hydroethylmethacrylates.
Alternatively it may be composed of a bioresorbable, or bioabsorbable biocompatible polymer, such as a polyanhydride, polyester, or mixtures thereof;
Poly-alpha-hydroxy acids (PGA), polylactic acid, copolymers of lactic and glycolic acids, and said polymers copolymerized with other polyesters such as epsilon -S caprolactone; copolymers having a glycolic acid ester and trimethylene carbonatelinkages, e.g. the copolymer in the MAXON (American Cyanamid Co~ y, Wayne NJ. 07470, USA) suture; polydioxanone; polyesters formed from diols and succinic and/or oxalic acid, isomorphic copolyoxalates and poly(alkylene) oxalates;
polymers made from unsyrnmetrically-substituted 1.4 - dioxane-2.5-diones.
One can also use silicon, connective tissue fibres such as collagen, polyglycolic acid, composite made of collagen and glycosaminoglucan (see USP 4,280,954).
The m~t~ l of the device is ~l~felably permeable to body liquids and substances in 15 order to facilitate for e.g. blood vessels to grow into the device. The material shall have qualities in order to hold and keep the nerve fibres in place. Connective tissue fibres such as collagen are suitable.
The device may be produced by using flexible tubes around which the 20 biocompatible material is moulded. The flexible tubes are bent to change ~e direction of the charmels from the first area of the proximal end to the second area of the distal end and vice versa to create channels ch~nging direction from white to grey matter. The tubes are then drawn out from the device.
25 Devices, such as plates intended for ch~ngin~ the direction from white to grey outside the means or between the means, can be produced as described in WO
90/05552.
The device is ple~erably delivered with a thread inserted in the channels. When 30 used, bundles of nerves are tied to the thread and drawn through the channels.
W O 9~04197 PCT/SEg7/01311 When used the device compri~ing nerve bundles or channels of biocompatible material co~ pi Schwans cells and/or other nerve growth promoting material are treated with a biocompatible glue co~"~ one or more growth factors.
5 The glue to be used according to the invention is preferably a fibrin glue co..~ g 50-200 mg /ml, preferably 100 mg/ml of fibrinogen and 0.2 ~lg - 20 ~lg per ml especially lllg - 5,ug per ml, especially 2.1 ,ug/ml of aFGF (acidic fibroblast growth factor).
10 The fibrin glue may be a fibrinogen based compound with double sealant components (Beringplast R P, Behring, Behringwerke AG, M~-gbulg, Germany), cont~inin~ a vial A with fibrinogen concentrate consisting of 115-232 mg dry substance, cont~ining a human plasma protein fraction with 65-115 mg fibrinogen and a human plasma l)rotei~l fraction with a factor XIII activity of 40-80 U, and a 15 vial B with aplot~ solution consisting of 1 ml solution cont~ining 1000 KI~J
bovine lung aproli~ and a vial C of thrombin consisting of 4.9- 11.1 mg dry substance cont~ining a human plasma pro~eill fraction with a thrombin activity of 400-600 IU and a vial D with a calcium chloride solution consisting of 2.5 ml solution cont~ining 14.7 mg calcium chloride 2H2O (40 mmol).
The advice of the supplier is followed and the aFGF is added to the vial A when used.
The invention will now be described with reference to the figures of which:
Fig la is a perspective view of one embodiment of the invention and the ends of the central nervous system at a gap, where the pathways in the central nerve systen is redirected, 30 Fig lb is a perspective view of another embodiment of the invention where the pathways are recoupled from white to white and from grey to grey mass, W 0 98/04197 ~l/~h~7/ol3 Fig 2 is a view from above of a device according to the invention clmci~ting of two plates, - 5 Fig 3 is a view from above as in Fig 2 showing possible m~rkin~ of the plates with figures in order to facilitate the threading of nerves through the plates.
Fig 4 A-F show the results from grafting of rat spinal cord, 4 A-C show microphotographs illustrating st~inings of sections through spinal cord se~ nt~, 4D
10 hindlimb function, 4E schematic illustration of white-to-grey matter nerve bridges and 4F summary of data from ~nim~l~ and Fig 5 A-F show morphology and sequential videoframes from experimental ~nim~
15 In the device la of Fig 1 the means 2 has the form of a cylinder with a proximal end area 5 and a distal end area 6 having first 8 and second 9 parts. The first parts 8 and the second parts 9 of the proximal and distal ends 5 and 6 are white and shaded respectively. The device contains channels 4 of which three are shown in the drawing. One channel 4 leads from the first part 8 of the proximal end area 5 to the 20 second part 9 of the distal area 6. Another channel leads from the second part 9 of the proximal end area 5 to the first part 8 of the distal end area 6. One of thechannels 4 ends in an opening 7 on the side area 14 of the device in order to beshunted passed the distal end of the CNS gap and introduced into the CNS furtherdown at a suitable angle through the white into the grey matter. The channels have 25 been threaded with bundles of nerves (not shown).
The end areas having parts marked in dirrelcl~ ways m~king it easy to see e.g. that channels coming out from the white first parts 8 of the ploxi",al end area 5 are to be inserted into the white matter 11 of the end area of the plox~l,al gap 10. Ch~nnel~
30 coming from the grey second area 9 in the distal end 6 of the device are inserted in the grey matter 13 of the end area of the distal gap 12. Correspondingly other , channels coming out from the white first 8 and grey second 9 part of the end areas 5 and 6 of the device are inserted into the mass of the end areas of the CNS gap having the same colour. With the device of figure 1 descending motor pathways from proximal white were coupled to distal grey matter and ascending pathways 5 from distal white to ~lox~ al grey matter according to the arrows.
The device of Fig. lb is intended to be used together with a material such as certain antibodies, that can induce growth in the nerve material. Therefore the pathwaysneed not to be redirected. The device comprises one means 20 in which two 10 channels 4 are shown to lead from the first part 8 of the proximal end area 5 to the first part 8 of the distal end area 6. Another channel 4 is shown to lead from the second part 9 of the proximal end area 5 to the second part 9 of the distal end areda 6. Thus, no redirection is made. The device of figure lb may also have channels ending in openings on the side area 14 to be shunted passed the gap and introduced 15 into the CNS further down (not shown).
Fig 2 shows the proximal and distal end areas of a device 1 consisting of two means 21 and 22 in the form of two plates with wholes 3 through which bundles of nerves or tubes filled with growth promoting material such as Schwans cells may be 20 threaded according to the dashed lines. The ~loxLl,.al and distal ends of the two plates are shown. The plates 21, 22 are marked lP and 2P respectively in order to be placed in the right order and with the pro~L~n~al ends towards the head of the patient.
The proximal end 5 of the first plate 21 marked " lP" has a white first part 8' and a grey second part 9' to show where to insert the tubes or nerve bundles into the white 25 and grey matter of the proximal CNS gap later on. The distal end 6 of the first plate is marl~ed in order to direct the threading of the nerves coming out of the first plate, the first part 8' being grey and the second part 9' being white. The proximal part 5 of the second plate 22 is marked to receive the nerves from the right part of the first plate in order to cha~ge the direction from white to grey. Thus, the first part 8 of the 30 proximal end 5 is white and the second part 9 is grey, the first 8 and second part 9 respectively of the distal end 6 of the second plate 22 being marked in the same WO 98/04197 PCr/SE97/01311 way, white and grey. The plates may change places but in such a case the crossing over from white to grey area will not take place between the plates but after the second plate. When used, glue is placed between the plates and at the site of insert or in the spinal cord.
It is also possible to mark the first and second part of the proximal area of the first plate white and grey as in figure 2 but instead of marking the areas of the distal end of the first plate and the proximal area of the second plate openings 7 of the holes 3 in these areas may be numbered in order to direct the threading as shown in 10 figure 3 .
When m~king and numbering the wholes it is possible to avoid or minimise crossing of the tubes or nerve bundles and to keep the redirection between white and greymatter in the same left or right part of the device and the spinal cord.
Tests showin~ Spinal Cord Repair in Adult Paraple~ic Rats and Partial Restoration of Hindlimb Function (Science, July 26, 1996, in press) Complete spinal cord gaps in adult rats were bridged with multiple intercostal nerve 20 grafts redirecting specific pathways from white to grey matter, and the grafted area stabilised by acidic fibroblast growth factor-cont~inin~; fibrin glue and compressive wiring of posterior spinal processes. Hindlimb function improved progressively during the first 6 months as assessed by two generally accepted scoring systems.The corticospinal tract regenerated through the grafted area to the lumbar 25 enlargement, as did several bulbospinal pathways. Together these data suggest a possible repair strategy for spinal cord injury.
To avoid ambiguities, and to model the most severe clinical scenario, we studiedadult rats with complete surgical transection of the spinal cord including removal of 30 5 mm of the cord at T8. Histology of excised pieces of spinal cord demonstrated complete transection (Fig. 4A). We then proceeded with a repair strategy (3).
We used peripheral nerve implants (4) to bridge the gap in the spinal cord (Fig. 4B
and C and Fig. 5B) and found that mllltiple fine nerve implants (18 nerves to bridge one gap) gave better precision than the use of fewer thicker nerves. To evade 5 oligodendroglial ~roleills that inhibit axon regeneration (5), we re-routed regenerating pathways from non-permissive white to permissive grey matter (6).
The peripheral nerve bridges thus redirected descending motor pathways from proximal white to distal grey matter, and ascending pathways from distal white to proximal grey matter (Fig. 4E), taking into account the specific anatomy of rat 10 descending and ascending pathways (7). To stabilise the lesioned area and theperipheral nerve bridges, the grafted area was filled with a fibrin-based tissue glue that does not impair nerve fibre growth (8), and fixed the v~leblal column in dorsiflexion by wiring (9).
15 Acidic FGF is a norrnal spinal cord constituent ( 10). Lacking a signal sequence, it is thought to be sequestered within cells, and released only after d~m~e.
Consequently, FGF may be involved in repair (11). It also decreases gliosis and enhances nerve fibre development in spinal cord grafts (12). Mixing aFGF into fibrin glue allows slow release (13).
~nim~ were followed over time for signs of functional recovery and rated by two independent blinded observers using the CBS (14) and the OFWS (15). Key responses were video-recorded. l~intllimb function in ~nim~l~ subjected to the five-step procedure improved significantly, be~innin~ three weeks after operation and25 continl-in~ through the year of observation (Fig. 4D). Anim~l~ subjected to nil~tçral treatment also improved, although to a lesser degree. Four different control groups (14 transection only, 5 cord removal only, 3 white-to-white matter bridging, 2 omissions of aFGF), did not improve (Fig. 4D). Improvement was manifest as appearance of a functional posture in hindlimbs (usually flexion at hips, 30 then knees, then dorsiflexion at ankles). In controls, hindlimbs remained ext~n~le(l and ext~rn~lly rotated. Improvement was symmetrical in 6 cases (28%), and asymmetrical in the rest. Locomotion involved trotting rather than ambling gait (Fig.
5 H-J). Hin-llimbs partially supported body weight and movements were noted in the three major joints. Such movements were not seen in any of the control groups.
We also found strongly statistically positive effects on contact placing scores of 5 both groups with full treatment (Fig. 4D), suggesting that functional recovery involves the corticospinal tract (2).
Anterograde wheat-germ agglutinin horseradish peroxidase (WGA-HRP) tracing from the sensorimotor cortices and retrograde WGA-HRP tracing from the lumbar 10 enlargements were used to document fibre tract regeneration (Fig. lF, 16). The spinal cord and brain were analysed and labelled nerve cell bodies counted (17).Sections from the engrafted area were analysed with cresyl violet or antibodies against neurofilament and glial fibrillary acidic protein (GFAP) to illustrate morphology, nerve fibres in the bridges, and the degree of gliosis. Anterograde 15 tracing is exemplified by one treated animal (Fig. 4F, SE, SF, SG) with labelled fibres descending in the dorsal funiculus of the proximal stump, traversing the bridging grafts, and reaching grey matter of the proximal portion of the distal stump.
Fibres descended at the interface between the dorsal funiculus and dorsal grey matter and ended along the dorsomedial aspect of the dorsal horn in regions 20 adjacent to substantial gelatinosa in the lumbar enlargement. The labelled fibres were thus found in areas corresponding to the pathway of the rat corticospinal tract as shown in rodent cortical ablation studies (7). In the four other anim~l~ analysed by anterograde tracing (Fig. 4F), labelled fibres traversed the bridging grafts and were found in grey matter to T11, Tl 1-12, T12 or L1-2. In four transected control 25 ~nim~l~ and in one animal subjected to white-to-white matter bridging plus aFGF, the corticospinal tracts did not reach the distal spinal cord stu~nps. Anterograde tracing of controls indicated no connections to the distal stumps (Fig. 4F).
Application of WGA-HRP to the lesioned lumbar spinal cord led to labelling of 30 motoneurons in layers III-V of hindlimb motor areas bilaterally in cortex cerebri in two of the three treated ~nim~l~ (Fig. SA). Labelled neurones were also observed in .. . . .
WO 98/041g7 PCT/SE97/01311 dorsal tegmentum, the lower limb areas of the red nuclei, reticular nuclei, and raphe nuclei in all treated ~nim~l~ A few raphe neurones (8 cells) were labelled in one of the three transected controls and one grafted animal without aFGF (56 cells).
Numerous raphe neurones were labelled in ~nim~l~ receiving the five-step 5 procedure. Thus a substantial number of regenerating descending axons, incl~ ing the corticospinal tract and other supraspinal neurones, appears essential for functional recovery. Anim~l~ with improvement of hind limb function showed evidence of regeneration of both the motor initiation and the voluntary gait modification cir-iuil~ to the spinal cord central pattern ge~ierator (18), suggesting 10 that these reconnections allowed ~nim~l~ to partially control their hin(llimhs. The degree of functional recovery appeared correlated to the degree of regeneration of motor fibre systems (Fig. 4F). GFAP-immunohistochemistry demonstrated large cysts and wide GFAP-poor gaps between the cord stumps (4.7~0.86 mm, n = 5) in C1 controls, whereas ~nim~l~ receiving the full repair strategy had significantly 15 shorter GFAP-poor gaps (0.7~t0. 19 mm, n = 4; pc 0.001, ANOVA). The bridge grafts in the latter group displayed rich neurofilament immunoreactivity.
Researchers have studied many different models of spinal cord injury in ~nim~lc.Incomplete spinal cord lesions such as hemisections, contusions, compressions, and dirre~ t chemical or mechanical partial lesions have generated valuable information 20 about reactive and compensatory changes, but several of these models are lesssuitable for studies of functional recovery caused by regeneration of cut axons We have shown that our procedure can lead to a substantial degree of structural andfunctional recovery in the completely transected adult rat spinal cord, including regeneration of pyramidal tract axons, hindlimb movements and weight support. It25 remains to be seen to which extent our technique is applicable to the chronic paraplegic state and to hllm~n~.
References:
30 1. E. Puchala, W. Windle, Exp. Neurol. 55, 1-42 (1977); L. Olson et al., Brain Res. Bull. 9, 519-537 (1982).
2. Y. Iwashita, S. Kaw~lchi M. Murata, Nature 367, 167-170 (1994); L.
Schnell et al., Nature 367, 170-173 (1994); B. Bregman, et al., Nature 378, 498-501 (1995).
Schnell et al., Nature 367, 170-173 (1994); B. Bregman, et al., Nature 378, 498-501 (1995).
3. Vertebrae T7-10 were exposed in adult 250-g female Sprague-Dawley rats, under halothane (1.5%) anaesthesia (res~ loly rate _60/min, rectal temperature <3~C below normal). Following T8 and T9 posterior laminectomies and bipolar cauterisation to control haemorrhage, a 5-mm T8 spinal cord segment was removed 10 with microscissors (Fig. 4A). Fighteen intercostal nerves collected in Hanks' were used to recormect and redirect pathways between the spinal cord stumps (Fig. 4E).
The floor of the cavity between the spinal cord stumps was covered by a thin gelfoam layer. Minced pieces of peripheral nerve were used to fill the angle between the gelfoam bottom and the ventral-most (white matter) surface of the cut 15 end of the distal spinal cord stump, producing a slanted floor allowing some physical support of those nerve bridges that went from deep (white matter) proximal sites to somewhat more dorsal (grey matter) distal sites. The cut ends of the intercostal nerve bridges were held against, and attached to the semi-dry spinal cord stump surfaces. The two fibrin glue sealant elements (Beriplast P, generously 20 provided by Behring, Germany) were prepared (see 8 & 13). aFGF (kindly provided by Drs Yihai Cao and Ralf Petterson, Ludwig Institute for Cancer Research, Stockholm) was mixed into the fibrinogen plus aplo~ solution. This solution was mixed with 10 !11 thrombin plus calcium chloride to form an aFGF-cont~ining (2.1~g/rnl glue) glue cast (final glue volume _ 10 ~11) in the engrafted area. The T7 and 25 T10 spinal processes were fixed in dorsiflexion with an S-shaped monofil~mentsurgical steel (DS-20, Ethicon) loop, fastened to the spinal column with non-absorbable circumspinal threads. In experimental ~nim~l~, one group was subjected to Imil~teral redirection and aFGF in the glue (URDaFGF), the other two groups were subjected to bilateral redirection and aFGF glue (BRDaFGF) using autografts30 (50%) mixed with allografts (I) or only autografts (II). Control ~nim~ls weresubjected to transection at T8 (C1), or removal of 5 mm cord segment (C2), or grafted with the same methods except HBSS replaced aFGF (BRDj, or grafted using only white-to-white matter connections (RBaFGF). ~nim~ls were caged on thick soft be~l~lin~, with heating from below during the first postoperative days. Manual emptying of the bladder was performed twice daily as long as needed. Antibiotics5 (Borgal, Hoechst, 15 mg/kg, subcutaneously) was injected once daily 7 days.
Decubitus sores on hinAlimbs were treated with iodine-soaked dressinp~s. Anim~l~were killed if severe sepsis (urinary tract infection), infected decubitus sores, or other wounds occurred. For the major experiments described here, the mortality was less than 10%. Experiments were approved by the animal research ethical 10 co~ ~ilLee of Stockholm. ~nim~l~ were sacrificed at different time points forhistological analyses but no earlier than one month after surgery to ensure complete degeneration of cut descending fibres in the distal stump (9).
~. S. David, and A. Aguayo, Science 214, 931-933 (1981); M. Benfey, and A.
15 Aguayo, Nature 296, 150-152 (1982); R. Bunge, Curr. Opin. Neurobiol. 3, 805 (1993).
5. T. Savio, and M. Schwab, Proc. Natl. Acad. Sci. USA 87, 4130 (1990); M.
Schwab, TINS 13, 452 (1990).
6. L. Nygren, K. Fuxe, G. Jonsson, L. Olson, Brain Res. 78, 377 (1974); R.
Kuang, M. Merline, K. Kalil, Development 120, 1937-1947 (1994).
7. L. Brown, Exp. Brain. Res. 13, 432 (1971).
8. H. Cheng, S. Almstrom, L. Olson, J. Neural Transplant. Plast. 5, 233 (1995).
9. H. Cheng, L. Olson, Exp. Neurol. 136, 149-161 (1995).
30 10. R. Elde, et al., Neuron 7, 349 (1991); Y. Cao, Thesis, Karolinska Institute (1993); M. Ko~hin~g~, H. Sanon, S. Whittemore, Exp. Neurol. 120, 32 (1993).
11. P. McNeil, L. Muthukri~hn~n E. Warder, P. D'Amore, J. Cell Biol. 109, 811 (1989).
5 12. M. Giacobini, B. Hoffer, G. Zerbe, L. Olson, Exp. Brain. Res. 86, 73 (1991).
13 . H. Cheng et al., Exp. Brain. Res. 104, 199 (1995).
14. K. Gale, H. Kerasidis, J. Wrathall, Expt. Neurol. 88, 123 (1985). Percentage10 functional deficit as indicated by the Combined Behavioral Score (CBS) was used for behavioural evaluation. The CBS (except hot plate), ranging from 100 points (complete paralysis) to 0 (normal), consists of motor score (0-45), toe spread (0-5), righting reflex (0-15), extension withdrawal (0-5), placing reflex (0-5), climbing on inclined plane (0-15), and swim test (0-10).
15. M. Beattie, J. Bresn~h~n, In: Criteria for the assessment of recovery of function: behavioural methods, M. Brown, et al., Eds. (American Paralysis Association, Springfield, New Jersey, 1989),pp. 16-25; D. Behrm~nn J. Bre~n~h~n,M. Beattie, B. Shah, J. Neurotrauma 9, 197-217 (1992). Open field waLking 20 measured the animal's gross locomotor ability during a 5-min testing period. Two coded ~nim~l.s were observed simlllt~neously to stim~ te locomotor activity and scored according to a modified Tarlov scale, ranging from 0 (flaccid paralysis) to 5 (normal walking). This scale was subdivided to more accurately reflect the pattern of recovery of locomotor function as follows: 0, no spontaneous movement; 1, 25 movement that is not reflexive, movement in the hip and/or knee, but not ankle; 2, movement of the limb in all three major joints; 3, active support, uncoordinated gait or occasional short bouts of co-or(lin~ted gait; 4, co-ordination of forelimbs and hin(llimbs in gait (trotting), waLks on knuckles or medial surface of foot or few toe drags); 5, normal.
16. L. Heimer, in Neuroanatomical Tract-Tracing Methods, L. Heimer, M.
Robards, L. Zaborszky, Eds. (Plenum Press, New York, 1981, 1989). For retrogradeHRP-tracing, six 0.1 ~11 5% WGA-HRP (Sigma) injections were made into the lumbar enlargement (L4-5, 25 mm distal to the distal graft-host interface) and 5 combined with an L6 transection to enhance HRP uptake. Positive and negative controls included injection of WGA-HRP with/without colchicin blockage or an acute cut at T8 (Fig. 4F). For anterograde HRP-tracing, a total of 2 ,ul 5% WGA-HRP was injected into the sensorimotor cortices using five 0.2 ~1 injections perside. Positive and negative controls are also given in Fig. 4F. ~nim~l~ were perfused 10 48 hours later (Ringer's solution, 2% paraformaldehyde, 10% sucrose). For immunohistochemistry of grafted areas, tissues were further treated with 4%
paraformaldehyde for 2 hours and then with polyvinylpyrrolidone (Sigma) for 6 weeks to allow sectioning of soft and bony tissue together. Cryostat 14-~1m sections for immunohistochemistry and 60- (brain and brainstem) or 90-!1m (spinal cord~
15 free-floating sections for tetrarnethylbenzidine histochemistry were collected.
17. M. Abercrombie, Anat. Rec. 94, 239 (1946). HRP-labelled neuron counts required presence of the nucleus. The total number of neurones (N) equals n t/(t +
d), where n is the nurnber of nuclei of HRP-labelled neurones counted times the 20 section period; t is the section thickness and d the average diameter of counted nuclel.
18. S. Grillner, in Control of Posture and Locomotion, R. Stein, K. Person, R.
Smith, J. Redford, Eds. (Plenum Press, New York, 1973), pp. 515-535.
19. We dedicate this paper to Arne Nylander. Supported by APA, the Swedish MRC, USPHS grants, Taiwan Chin-Lin Fund and NSC. We thank the late Jan Arvidsson for valuable tracing advice, and assistance from Susanne Alms~om, Monica Casserlov, Kjell Erlandsson, and Ida Engqvist.
CA 0226l2l6 l999-0l-2l W O g8/04197 P~ 7lol3 21 Figure legends:
Fig. 4. (A) Microphotograph illustrating cresyl violet-stained transverse section through removed spinal cord se~ment Bar: 250 ~lm. (B) Sagittal section of a 5 repaired junction area stained with cresyl violet. Note nerve bridge grafts. Boxed area indicates the redirected fasciculus gracilis (upper) and dorsal corticospinal tract (lower) between the plo~ilual (left) and distal stump (right). Bar: 1000 ~lm. (C) Adjacent section immllnostained with MAb to neurofil~ment protein 70,000.
Numerous nerve fibres are present in the intercostal nerve bridges. Bar: 200 ~lm. (D) 10 Hindlimb function in the 7 different groups (see 3). Hindlimbs were assessed independently (except inclined plane test) to identify asymmetric recovery. Animal scores were generated by averaging hinr~limb scores. Open field walking (upper panel) measured the animal's gross locomotor ability during a 5-min testing period.
In the treated groups (BRDaFGF I &II), the scores improved significantly more than 15 in the controls (C l+C2) from the third week on (Mann-Whitney). Unilaterally treated anim~ls (URDaFGF) improved to a lesser degree as seen 6 months after surgery. Percentage functional deficit as indicated by the CBS is illustrated in ~e middle panel. ~nim~lc subjected to the five-step procedure improved significantly compared both to ~nim~lc in which the spinal cord was only transected (C1) and 20 ~nim~lc with removal of a cord segment (C2, ANOVA). Contact placing score (lower panel) indicates functional recovery of the corticospinal tract and is significantly better in ~nim~lc subjected to the five-step procedure than controls until 6 months (Mann-Whitney). ****: P < 0.0001; ***: p < 0.001; **: p < 0.01; *:
p < 0.05. (E) Schematic illustration of white-to-grey matter nerve bridges. Pieces of 25 intercostal nerves were used to reconnect and redirect pathways between the spinal cord stumps, ThVII, ThIX: seventh and ninth thoracic segment). For each redirected tract, one to three intercostal nerves were used. (F) Summary of data from ~nim~l~
in which both open field walking scoring and HRP-tracing data were collected.
~nking tracing results from 0 (negative) to 10 (normal), the full repa~r ~nim~lc30 differ significantly from controls (p < 0.001, Mann-Whitney).
Fig. 5. Morphology and sequential videoframes from experimental ~nim~l~. (A) Tetramethylbenzidine histochemistry of cortex cerebri (1 mm posterior to bregma)in a rat one year after the five-step procedure and 48 hrs after retrograde WGA-HRP
tracing from the lumbar enlar~em~nt Labelled pyramidal cells are found in the 5 hindlimb motor area. Bar: 100 ~lm. (B) Cresyl violet cross-section of bridge area in a treated rat after 4 months. Note 15 nerve bundles (*) and blood vessels (~). Bar:
600 ~lm. (C-G) Anterograde transport of WGA-HRP after injection into sensorimotor cortex in a normal rat (C, schem~tically depicted in D) and a treated rat 3 months after surgery (F and G, schematically depicted in E). Sagittal section of 10 the bridge area (F) shows labelled fibres traversing bridging grafts (*) and reaching the distal stump (right). Some tissue was lost during free-floating processing of section (~). Transverse section of the lumbar enlargement (G) shows labelled fibres in the dorsal funiculus at the white/grey matter interface, and adjacent to substantial gelatinosa. Bar: 200 ,um in C and G, 500 !lm in F. (H-J) Sequential videoframes 15 (interval between each frame: 0.12 sec) of 3 rats subjected to complete five-step procedures. (H) Animal after 3 months. Note that hindlimbs can support body weight during forward stepping. Toe dragging was absent in this animal. (I & J) Rats climbing a 45-degree inclined plane one year (I) or 3 months (J) after surgery.
Hindlimbs partially supported body weight and displayed movements in all three 20 major joints. A trotting, rather than ambling or random movement of the four limbs was noted (data not shown), although the hindlimb toes dragged during waLking in I.
The floor of the cavity between the spinal cord stumps was covered by a thin gelfoam layer. Minced pieces of peripheral nerve were used to fill the angle between the gelfoam bottom and the ventral-most (white matter) surface of the cut 15 end of the distal spinal cord stump, producing a slanted floor allowing some physical support of those nerve bridges that went from deep (white matter) proximal sites to somewhat more dorsal (grey matter) distal sites. The cut ends of the intercostal nerve bridges were held against, and attached to the semi-dry spinal cord stump surfaces. The two fibrin glue sealant elements (Beriplast P, generously 20 provided by Behring, Germany) were prepared (see 8 & 13). aFGF (kindly provided by Drs Yihai Cao and Ralf Petterson, Ludwig Institute for Cancer Research, Stockholm) was mixed into the fibrinogen plus aplo~ solution. This solution was mixed with 10 !11 thrombin plus calcium chloride to form an aFGF-cont~ining (2.1~g/rnl glue) glue cast (final glue volume _ 10 ~11) in the engrafted area. The T7 and 25 T10 spinal processes were fixed in dorsiflexion with an S-shaped monofil~mentsurgical steel (DS-20, Ethicon) loop, fastened to the spinal column with non-absorbable circumspinal threads. In experimental ~nim~l~, one group was subjected to Imil~teral redirection and aFGF in the glue (URDaFGF), the other two groups were subjected to bilateral redirection and aFGF glue (BRDaFGF) using autografts30 (50%) mixed with allografts (I) or only autografts (II). Control ~nim~ls weresubjected to transection at T8 (C1), or removal of 5 mm cord segment (C2), or grafted with the same methods except HBSS replaced aFGF (BRDj, or grafted using only white-to-white matter connections (RBaFGF). ~nim~ls were caged on thick soft be~l~lin~, with heating from below during the first postoperative days. Manual emptying of the bladder was performed twice daily as long as needed. Antibiotics5 (Borgal, Hoechst, 15 mg/kg, subcutaneously) was injected once daily 7 days.
Decubitus sores on hinAlimbs were treated with iodine-soaked dressinp~s. Anim~l~were killed if severe sepsis (urinary tract infection), infected decubitus sores, or other wounds occurred. For the major experiments described here, the mortality was less than 10%. Experiments were approved by the animal research ethical 10 co~ ~ilLee of Stockholm. ~nim~l~ were sacrificed at different time points forhistological analyses but no earlier than one month after surgery to ensure complete degeneration of cut descending fibres in the distal stump (9).
~. S. David, and A. Aguayo, Science 214, 931-933 (1981); M. Benfey, and A.
15 Aguayo, Nature 296, 150-152 (1982); R. Bunge, Curr. Opin. Neurobiol. 3, 805 (1993).
5. T. Savio, and M. Schwab, Proc. Natl. Acad. Sci. USA 87, 4130 (1990); M.
Schwab, TINS 13, 452 (1990).
6. L. Nygren, K. Fuxe, G. Jonsson, L. Olson, Brain Res. 78, 377 (1974); R.
Kuang, M. Merline, K. Kalil, Development 120, 1937-1947 (1994).
7. L. Brown, Exp. Brain. Res. 13, 432 (1971).
8. H. Cheng, S. Almstrom, L. Olson, J. Neural Transplant. Plast. 5, 233 (1995).
9. H. Cheng, L. Olson, Exp. Neurol. 136, 149-161 (1995).
30 10. R. Elde, et al., Neuron 7, 349 (1991); Y. Cao, Thesis, Karolinska Institute (1993); M. Ko~hin~g~, H. Sanon, S. Whittemore, Exp. Neurol. 120, 32 (1993).
11. P. McNeil, L. Muthukri~hn~n E. Warder, P. D'Amore, J. Cell Biol. 109, 811 (1989).
5 12. M. Giacobini, B. Hoffer, G. Zerbe, L. Olson, Exp. Brain. Res. 86, 73 (1991).
13 . H. Cheng et al., Exp. Brain. Res. 104, 199 (1995).
14. K. Gale, H. Kerasidis, J. Wrathall, Expt. Neurol. 88, 123 (1985). Percentage10 functional deficit as indicated by the Combined Behavioral Score (CBS) was used for behavioural evaluation. The CBS (except hot plate), ranging from 100 points (complete paralysis) to 0 (normal), consists of motor score (0-45), toe spread (0-5), righting reflex (0-15), extension withdrawal (0-5), placing reflex (0-5), climbing on inclined plane (0-15), and swim test (0-10).
15. M. Beattie, J. Bresn~h~n, In: Criteria for the assessment of recovery of function: behavioural methods, M. Brown, et al., Eds. (American Paralysis Association, Springfield, New Jersey, 1989),pp. 16-25; D. Behrm~nn J. Bre~n~h~n,M. Beattie, B. Shah, J. Neurotrauma 9, 197-217 (1992). Open field waLking 20 measured the animal's gross locomotor ability during a 5-min testing period. Two coded ~nim~l.s were observed simlllt~neously to stim~ te locomotor activity and scored according to a modified Tarlov scale, ranging from 0 (flaccid paralysis) to 5 (normal walking). This scale was subdivided to more accurately reflect the pattern of recovery of locomotor function as follows: 0, no spontaneous movement; 1, 25 movement that is not reflexive, movement in the hip and/or knee, but not ankle; 2, movement of the limb in all three major joints; 3, active support, uncoordinated gait or occasional short bouts of co-or(lin~ted gait; 4, co-ordination of forelimbs and hin(llimbs in gait (trotting), waLks on knuckles or medial surface of foot or few toe drags); 5, normal.
16. L. Heimer, in Neuroanatomical Tract-Tracing Methods, L. Heimer, M.
Robards, L. Zaborszky, Eds. (Plenum Press, New York, 1981, 1989). For retrogradeHRP-tracing, six 0.1 ~11 5% WGA-HRP (Sigma) injections were made into the lumbar enlargement (L4-5, 25 mm distal to the distal graft-host interface) and 5 combined with an L6 transection to enhance HRP uptake. Positive and negative controls included injection of WGA-HRP with/without colchicin blockage or an acute cut at T8 (Fig. 4F). For anterograde HRP-tracing, a total of 2 ,ul 5% WGA-HRP was injected into the sensorimotor cortices using five 0.2 ~1 injections perside. Positive and negative controls are also given in Fig. 4F. ~nim~l~ were perfused 10 48 hours later (Ringer's solution, 2% paraformaldehyde, 10% sucrose). For immunohistochemistry of grafted areas, tissues were further treated with 4%
paraformaldehyde for 2 hours and then with polyvinylpyrrolidone (Sigma) for 6 weeks to allow sectioning of soft and bony tissue together. Cryostat 14-~1m sections for immunohistochemistry and 60- (brain and brainstem) or 90-!1m (spinal cord~
15 free-floating sections for tetrarnethylbenzidine histochemistry were collected.
17. M. Abercrombie, Anat. Rec. 94, 239 (1946). HRP-labelled neuron counts required presence of the nucleus. The total number of neurones (N) equals n t/(t +
d), where n is the nurnber of nuclei of HRP-labelled neurones counted times the 20 section period; t is the section thickness and d the average diameter of counted nuclel.
18. S. Grillner, in Control of Posture and Locomotion, R. Stein, K. Person, R.
Smith, J. Redford, Eds. (Plenum Press, New York, 1973), pp. 515-535.
19. We dedicate this paper to Arne Nylander. Supported by APA, the Swedish MRC, USPHS grants, Taiwan Chin-Lin Fund and NSC. We thank the late Jan Arvidsson for valuable tracing advice, and assistance from Susanne Alms~om, Monica Casserlov, Kjell Erlandsson, and Ida Engqvist.
CA 0226l2l6 l999-0l-2l W O g8/04197 P~ 7lol3 21 Figure legends:
Fig. 4. (A) Microphotograph illustrating cresyl violet-stained transverse section through removed spinal cord se~ment Bar: 250 ~lm. (B) Sagittal section of a 5 repaired junction area stained with cresyl violet. Note nerve bridge grafts. Boxed area indicates the redirected fasciculus gracilis (upper) and dorsal corticospinal tract (lower) between the plo~ilual (left) and distal stump (right). Bar: 1000 ~lm. (C) Adjacent section immllnostained with MAb to neurofil~ment protein 70,000.
Numerous nerve fibres are present in the intercostal nerve bridges. Bar: 200 ~lm. (D) 10 Hindlimb function in the 7 different groups (see 3). Hindlimbs were assessed independently (except inclined plane test) to identify asymmetric recovery. Animal scores were generated by averaging hinr~limb scores. Open field walking (upper panel) measured the animal's gross locomotor ability during a 5-min testing period.
In the treated groups (BRDaFGF I &II), the scores improved significantly more than 15 in the controls (C l+C2) from the third week on (Mann-Whitney). Unilaterally treated anim~ls (URDaFGF) improved to a lesser degree as seen 6 months after surgery. Percentage functional deficit as indicated by the CBS is illustrated in ~e middle panel. ~nim~lc subjected to the five-step procedure improved significantly compared both to ~nim~lc in which the spinal cord was only transected (C1) and 20 ~nim~lc with removal of a cord segment (C2, ANOVA). Contact placing score (lower panel) indicates functional recovery of the corticospinal tract and is significantly better in ~nim~lc subjected to the five-step procedure than controls until 6 months (Mann-Whitney). ****: P < 0.0001; ***: p < 0.001; **: p < 0.01; *:
p < 0.05. (E) Schematic illustration of white-to-grey matter nerve bridges. Pieces of 25 intercostal nerves were used to reconnect and redirect pathways between the spinal cord stumps, ThVII, ThIX: seventh and ninth thoracic segment). For each redirected tract, one to three intercostal nerves were used. (F) Summary of data from ~nim~l~
in which both open field walking scoring and HRP-tracing data were collected.
~nking tracing results from 0 (negative) to 10 (normal), the full repa~r ~nim~lc30 differ significantly from controls (p < 0.001, Mann-Whitney).
Fig. 5. Morphology and sequential videoframes from experimental ~nim~l~. (A) Tetramethylbenzidine histochemistry of cortex cerebri (1 mm posterior to bregma)in a rat one year after the five-step procedure and 48 hrs after retrograde WGA-HRP
tracing from the lumbar enlar~em~nt Labelled pyramidal cells are found in the 5 hindlimb motor area. Bar: 100 ~lm. (B) Cresyl violet cross-section of bridge area in a treated rat after 4 months. Note 15 nerve bundles (*) and blood vessels (~). Bar:
600 ~lm. (C-G) Anterograde transport of WGA-HRP after injection into sensorimotor cortex in a normal rat (C, schem~tically depicted in D) and a treated rat 3 months after surgery (F and G, schematically depicted in E). Sagittal section of 10 the bridge area (F) shows labelled fibres traversing bridging grafts (*) and reaching the distal stump (right). Some tissue was lost during free-floating processing of section (~). Transverse section of the lumbar enlargement (G) shows labelled fibres in the dorsal funiculus at the white/grey matter interface, and adjacent to substantial gelatinosa. Bar: 200 ,um in C and G, 500 !lm in F. (H-J) Sequential videoframes 15 (interval between each frame: 0.12 sec) of 3 rats subjected to complete five-step procedures. (H) Animal after 3 months. Note that hindlimbs can support body weight during forward stepping. Toe dragging was absent in this animal. (I & J) Rats climbing a 45-degree inclined plane one year (I) or 3 months (J) after surgery.
Hindlimbs partially supported body weight and displayed movements in all three 20 major joints. A trotting, rather than ambling or random movement of the four limbs was noted (data not shown), although the hindlimb toes dragged during waLking in I.
Claims (14)
1. A medical device (1) of a biocompatible material for use in the treatment of a gap or defect in the central nerve system comprising one or more means (2,20,21,22) containing connections such as holes (3) or channels (4) arranged for receiving nerve growht promoting materials or substances, which device has a proximal (5) and a distal (6) end area comprising openings (7) from the connections (3,4) characterized in that the device is marked and arranged for coupling nerves from the grey and white matter of the central nervous system at the proximal end to certain marked areas in the proximal end area and nerves in the grey and white matter at the distal end to certain marked areas in the distal end area.
2. A medical device according to claim 1, characterized in that the device (1) is marked and arranged for coupling nerves from the grey matter of the central nervous system at the proximal end to nerves in the grey matter at the distal end and nerves in the white matter of the central nervous system at the proximal end to nerves in the white matter at the distal end.
3. A medical device (1) according to claim 1, characterised in that the device (1) is marked and arranged for coupling nerves in the grey matter of the central nervous system at the proximal end to nerves in the white matter of the central nervous system at the distal end and vice versa, e.g. by being marked or by direction of the connections (4).
4. A means (2,20,21) according to claim 1-3, characterised in that the area of the proximal (5) and distal (6) ends of the means (2,20,21) is divided in a first part (8), that is connected to the white matter of the spinal cord and a second part (9), that is connected to the grey matter of the spinal cord.
5. A means according to anyone of claims 1-4, characterised in that the second part (9) is a central area and the first part (8) is a peripheral area situated substantially around the central area.
6. A means according to claim 1,3-5, characterised in that the means (2) comprises channels (4) bridging openings (7) in the first part (8) of the area of the proximal end (5) and openings (7) in the second part (9) of the area of the distal end (6) and channels (4) bridging openings (7) in a second part (9) of the area of the proximal end (5) and openings (7) in a first part (8) of the area of the distal end (6).
7. A means according to claim 1,2,4-5, characterised in that the means (20) comprises channels (4) bridging openings (7) in the first part (8) of the area of the proximal end (5) and openings (7) in the first part (8) of the area of the distal end (6) and channels (4) bridging openings (7) in a second part (9) of the area of the proximal end (5) and openings (7) in a second part (9) of the area of the distal end (6).
8. A means according to anyone of claims 1-7 having openings (7) with a diameter d and a length 1 greater than d creating a side area (14) in the length direction,whereby one ore more channels (4) are arranged to end with their openings (7) inthe side area (14).
9. A means (2,20) according to anyone of claims 1-8, characterised in that it has a substantially cylindrical form.
10. A means (21, 22) according to anyone of claims 1-4, characterised in that it has a substantially flat or plate like form.
11. A device (1) according to anyone of claims 1-10, characterised in that the device comprises two or more means (21, 22) with substantially flat or plate like form and possibly tubings to be filled with growth promoting material and threaded through the holes.
12. A device (1) according to anyone of claims 1-11, characterised in that it comprises a means (2,20) with substantially cylindrical form and one or more means (21, 22) having a substantially flat or plate like form.
13. A device (1) according to anyone of claims 1-12, characterised in that it contains a growth promoting material.
14. A method for restoring a deficiency in the spinal cord on humans comprising filling a device of a biocompatible material according to anyone of claims 1-13,with nerves and/or Schwans cells, possibly aslo growth promoting material, biocompatible glue and antibodies and connecting the nerves of the spinal cord.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9602879-0 | 1996-07-26 | ||
| SE9602879A SE9602879D0 (en) | 1996-07-26 | 1996-07-26 | Medical device |
| PCT/SE1997/001311 WO1998004197A1 (en) | 1996-07-26 | 1997-07-24 | Medical device for treatment of a gap or defect in the central nerve system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2261216A1 true CA2261216A1 (en) | 1998-02-05 |
Family
ID=20403483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002261216A Abandoned CA2261216A1 (en) | 1996-07-26 | 1997-07-24 | Medical device for treatment of a gap or defect in the central nerve system |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6235041B1 (en) |
| EP (1) | EP0918488B8 (en) |
| JP (1) | JP2000517206A (en) |
| AT (1) | ATE293393T1 (en) |
| AU (1) | AU732199B2 (en) |
| CA (1) | CA2261216A1 (en) |
| DE (1) | DE69733068T2 (en) |
| DK (1) | DK0918488T3 (en) |
| ES (1) | ES2241052T3 (en) |
| PT (1) | PT918488E (en) |
| SE (1) | SE9602879D0 (en) |
| WO (1) | WO1998004197A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972168B2 (en) * | 2001-08-13 | 2005-12-06 | University Of Florida Research Foundation, Incorporated | Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| US20070100358A2 (en) * | 2002-08-01 | 2007-05-03 | Texas Scottish Rite Hospital For Children | A Biomimetic Synthetic Nerve Implant |
| WO2005046457A2 (en) * | 2003-11-05 | 2005-05-26 | Texas Scottish Rite Hospital For Children | A biomimetic biosynthetic nerve implant |
| US8146602B2 (en) * | 2003-01-29 | 2012-04-03 | Taipei Veterans General Hospital | Method and mixture for nerve root repair |
| WO2004112192A2 (en) * | 2003-06-12 | 2004-12-23 | Tereza Miguel Meneguim | Connecting device for nerve-cords |
| US7369900B2 (en) * | 2004-05-08 | 2008-05-06 | Bojan Zdravkovic | Neural bridge devices and methods for restoring and modulating neural activity |
| US20080228240A1 (en) * | 2004-06-17 | 2008-09-18 | Edell David J | Long Term Bi-Directional Axon-Electronic Communication System |
| US8206448B2 (en) | 2004-10-29 | 2012-06-26 | Spinal Restoration, Inc. | Injection of fibrin sealant using reconstituted components in spinal applications |
| US7597687B2 (en) * | 2004-10-29 | 2009-10-06 | Spinal Restoration, Inc. | Injection of fibrin sealant including an anesthetic in spinal applications |
| US20060019869A1 (en) * | 2004-07-23 | 2006-01-26 | Thomas Dimauro M | Intradiscal anti-inflammatory therapy involving autologous adiponectin |
| US20110213464A1 (en) * | 2004-10-29 | 2011-09-01 | Whitlock Steven I | Injection of fibrin sealant in the absence of corticosteroids in spinal applications |
| PL1998690T3 (en) * | 2006-03-29 | 2019-12-31 | Swenora Biotech Ab | A method for manufacturing a nerve regeneration device |
| US7783363B2 (en) | 2006-10-23 | 2010-08-24 | Artis Nanomedica, Inc. | Neural bridge gateway and calibrator |
| US7783360B2 (en) | 2006-10-23 | 2010-08-24 | Bojan Zdravkovic | Sensory system |
| WO2008063878A2 (en) * | 2006-11-06 | 2008-05-29 | Bonwrx, Inc. | Nerve regeneration device |
| US20080305148A1 (en) * | 2007-03-19 | 2008-12-11 | National Yang Ming University | Treatment of spinal injuries using human umbilical mesenchymal stem cells |
| EP2148634A1 (en) * | 2007-05-15 | 2010-02-03 | Axongen Ab | Fibrin-based nerve repair conduit and method of producing the same |
| GB0717168D0 (en) * | 2007-09-04 | 2007-10-17 | Ucl Business Plc | Biomaterial scaffolds for controlled tissue growth |
| CN101278865B (en) * | 2008-05-09 | 2010-04-07 | 南通大学 | Partition type tissue engineering spinal cord |
| US9572909B2 (en) * | 2009-09-14 | 2017-02-21 | Virginia Commonwealth University | Electrospun nerve guides for nerve regeneration designed to modulate nerve architecture |
| WO2013084137A1 (en) | 2011-12-06 | 2013-06-13 | Bioarctic Neuroscience Ab | Spinal cord devices and methods for promoting axonal regeneration |
| US10813643B2 (en) * | 2017-10-19 | 2020-10-27 | Axogen Corporation | Materials and methods for breast neurotization with nerve grafts |
| KR102406052B1 (en) * | 2018-11-15 | 2022-06-07 | 옥소젠 코포레이션 | Materials and methods for repairing nerves with nerve grafts of animal origin |
| US11147558B2 (en) | 2018-11-15 | 2021-10-19 | Axogen Corporation | Materials and methods for nerve repair with animal-sourced grafts |
| IL281044B (en) * | 2021-02-23 | 2022-04-01 | Reddress Ltd | Method and kit for treating damaged nerves |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3786817A (en) * | 1972-06-01 | 1974-01-22 | Palma J | Method and apparatus for aiding severed nerves to join |
| US3833002A (en) * | 1973-09-10 | 1974-09-03 | J Palma | Apparatus for aiding severed nerves to join |
| US4669474A (en) * | 1984-01-12 | 1987-06-02 | Minnesota Mining And Manufacturing Company | Absorbable nerve repair device and method |
| US4759764A (en) | 1985-05-24 | 1988-07-26 | Clayton Foundation For Research | Peripheral nerve regeneration |
| SE457598B (en) * | 1987-03-09 | 1989-01-16 | Astra Meditec Ab | PROTEST FOR HOPE SPLITING OF NERVENDENDS |
| IL82830A (en) * | 1987-06-09 | 1992-03-29 | Simeone Rochkind | Apparatus for inducing functional regeneration of nerve fibres at an injured site of the spinal cord |
| US5011486A (en) * | 1988-11-18 | 1991-04-30 | Brown University Research Foundation | Composite nerve guidance channels |
| US4963146A (en) * | 1989-04-20 | 1990-10-16 | Colla-Tec Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration |
| US4963416A (en) | 1989-11-13 | 1990-10-16 | W. L. Gore & Associates, Inc. | Method to reduce the damage caused by ionizing radiation to polyurethane/porous expanded polytetrafluroethylene composites by use of hindered phenols |
| GB9213694D0 (en) * | 1992-06-27 | 1992-08-12 | Keynes Roger J | Improvements in or relating to neuroregeneration |
| US5584885A (en) * | 1994-04-28 | 1996-12-17 | Seckel; Brooke R. | Nerve regeneration chamber |
| US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
-
1996
- 1996-07-26 SE SE9602879A patent/SE9602879D0/en unknown
-
1997
- 1997-07-24 AU AU37906/97A patent/AU732199B2/en not_active Ceased
- 1997-07-24 DK DK97934833T patent/DK0918488T3/en active
- 1997-07-24 JP JP10508740A patent/JP2000517206A/en active Pending
- 1997-07-24 ES ES97934833T patent/ES2241052T3/en not_active Expired - Lifetime
- 1997-07-24 EP EP97934833A patent/EP0918488B8/en not_active Expired - Lifetime
- 1997-07-24 CA CA002261216A patent/CA2261216A1/en not_active Abandoned
- 1997-07-24 AT AT97934833T patent/ATE293393T1/en active
- 1997-07-24 US US09/230,509 patent/US6235041B1/en not_active Expired - Lifetime
- 1997-07-24 DE DE69733068T patent/DE69733068T2/en not_active Expired - Lifetime
- 1997-07-24 WO PCT/SE1997/001311 patent/WO1998004197A1/en active IP Right Grant
- 1997-07-24 PT PT97934833T patent/PT918488E/en unknown
-
2001
- 2001-01-29 US US09/770,460 patent/US6808530B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6235041B1 (en) | 2001-05-22 |
| PT918488E (en) | 2005-09-30 |
| EP0918488B8 (en) | 2005-06-15 |
| ATE293393T1 (en) | 2005-05-15 |
| ES2241052T3 (en) | 2005-10-16 |
| AU3790697A (en) | 1998-02-20 |
| JP2000517206A (en) | 2000-12-26 |
| US6808530B2 (en) | 2004-10-26 |
| DE69733068T2 (en) | 2006-03-09 |
| SE9602879D0 (en) | 1996-07-26 |
| US20010017138A1 (en) | 2001-08-30 |
| AU732199B2 (en) | 2001-04-12 |
| DE69733068D1 (en) | 2005-05-25 |
| DK0918488T3 (en) | 2005-08-22 |
| WO1998004197A1 (en) | 1998-02-05 |
| EP0918488B1 (en) | 2005-04-20 |
| EP0918488A1 (en) | 1999-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0918488B1 (en) | Medical device for treatment of a gap or defect in the central nerve system | |
| Lundborg | A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance | |
| Madison et al. | Entubulation repair with protein additives increases the maximum nerve gap distance successfully bridged with tubular prostheses | |
| Yao et al. | Controlling dispersion of axonal regeneration using a multichannel collagen nerve conduit | |
| Hildebrand et al. | Rabbit knee model of post-traumatic joint contractures: the long-term natural history of motion loss and myofibroblasts | |
| CN102231992B (en) | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries | |
| Valentin-Opran | Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report | |
| Barcelos et al. | Inside‐out vein graft and inside‐out artery graft in rat sciatic nerve repair | |
| AU2012349725B2 (en) | Spinal cord devices and methods for promoting axonal regeneration | |
| Bertelli et al. | Contralateral motor rootlets and ipsilateral nerve transfers in brachial plexus reconstruction | |
| AU751620B2 (en) | A method for treating a deficiency in a spinal cord | |
| Nicolas et al. | Resorbable nerve wraps: can they be overtightened? | |
| Brunelli et al. | Experimental repair of spinal cord lesions by grafting from CNS to PNS | |
| Raffe | Principles of peripheral nerve repair | |
| RU2173103C1 (en) | Method for performing entero-enteroanastomosis | |
| Rubio et al. | Clinical applications of plasma growth factors | |
| Farmer et al. | Healing of a split flexor tendon graft—an experimental study in chickens | |
| RU2216290C2 (en) | Method for surgical treatment of ivdegree burns of sacral area | |
| SU1090371A1 (en) | Method of making the model of false joint | |
| Chen | Bone regeneration at a rib donor site in dogs | |
| Huber et al. | Esophageal abomasal anastomosis in lambs | |
| Ruskin | The effects of chitosan on nerve regeneration | |
| Zeineh et al. | Managing acute nerve injuries in extremities | |
| Lovric | Biological and biophysical strategies to enhance tendon-bone interface healing in intra-articular and extra-articular animal models | |
| GangaI et al. | Sciatic nerve regeneration in rats by a nerve conduit engineering with a membrane derived from natural latex1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |